AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 226 filers reported holding AMICUS THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.35 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $16,990 | -2.9% | 1,397,095 | +0.3% | 0.00% | 0.0% |
| Q2 2023 | $17,492 | +7.4% | 1,392,614 | -5.2% | 0.00% | 0.0% |
| Q1 2023 | $16,292 | -10.5% | 1,469,002 | -1.4% | 0.00% | -33.3% |
| Q4 2022 | $18,195 | -99.9% | 1,490,195 | +2.2% | 0.00% | +50.0% |
| Q3 2022 | $15,230,000 | -3.3% | 1,458,720 | -0.5% | 0.00% | 0.0% |
| Q2 2022 | $15,745,000 | +13.8% | 1,465,995 | +0.3% | 0.00% | +100.0% |
| Q1 2022 | $13,837,000 | -42.0% | 1,461,131 | -29.2% | 0.00% | -50.0% |
| Q4 2021 | $23,852,000 | -10.1% | 2,065,142 | -25.6% | 0.00% | 0.0% |
| Q3 2021 | $26,523,000 | +7.2% | 2,777,248 | +8.2% | 0.00% | 0.0% |
| Q2 2021 | $24,752,000 | +20.1% | 2,567,676 | +23.1% | 0.00% | 0.0% |
| Q1 2021 | $20,606,000 | -56.5% | 2,085,672 | +1.8% | 0.00% | -60.0% |
| Q4 2020 | $47,320,000 | +181.3% | 2,049,362 | +72.0% | 0.01% | +150.0% |
| Q3 2020 | $16,822,000 | -0.5% | 1,191,337 | +6.3% | 0.00% | 0.0% |
| Q2 2020 | $16,908,000 | +92.6% | 1,121,253 | +18.0% | 0.00% | +100.0% |
| Q1 2020 | $8,777,000 | -4.5% | 949,845 | +0.7% | 0.00% | 0.0% |
| Q4 2019 | $9,191,000 | +33.3% | 943,647 | +9.8% | 0.00% | 0.0% |
| Q3 2019 | $6,895,000 | -36.1% | 859,777 | -0.6% | 0.00% | -50.0% |
| Q2 2019 | $10,790,000 | -8.1% | 864,581 | +0.1% | 0.00% | 0.0% |
| Q1 2019 | $11,741,000 | +41.6% | 863,345 | -0.2% | 0.00% | +100.0% |
| Q4 2018 | $8,289,000 | -72.5% | 865,277 | -65.2% | 0.00% | -75.0% |
| Q3 2018 | $30,088,000 | -67.4% | 2,488,634 | -57.9% | 0.00% | -71.4% |
| Q2 2018 | $92,407,000 | +24.1% | 5,915,945 | +19.5% | 0.01% | +16.7% |
| Q1 2018 | $74,442,000 | -42.9% | 4,949,633 | -45.4% | 0.01% | -42.9% |
| Q4 2017 | $130,421,000 | +6.9% | 9,063,311 | +12.0% | 0.02% | 0.0% |
| Q3 2017 | $122,028,000 | +330.5% | 8,092,031 | +187.5% | 0.02% | +320.0% |
| Q2 2017 | $28,345,000 | +39.9% | 2,814,841 | -0.9% | 0.01% | +25.0% |
| Q1 2017 | $20,262,000 | +34.0% | 2,841,830 | -6.6% | 0.00% | +33.3% |
| Q4 2016 | $15,118,000 | -52.9% | 3,041,930 | -29.9% | 0.00% | -50.0% |
| Q3 2016 | $32,111,000 | -0.0% | 4,339,335 | -26.3% | 0.01% | -14.3% |
| Q2 2016 | $32,126,000 | -35.6% | 5,883,948 | -0.3% | 0.01% | -36.4% |
| Q1 2016 | $49,864,000 | -13.3% | 5,901,048 | -0.5% | 0.01% | -8.3% |
| Q4 2015 | $57,512,000 | -30.2% | 5,929,068 | +0.7% | 0.01% | -33.3% |
| Q3 2015 | $82,373,000 | -0.0% | 5,887,965 | +1.1% | 0.02% | +5.9% |
| Q2 2015 | $82,414,000 | +1119.3% | 5,824,300 | +837.5% | 0.02% | +1600.0% |
| Q1 2015 | $6,759,000 | – | 621,249 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |